Inovio Pharmaceuticals Inc
NASDAQ:INO

  • LAST PRICE
    10.3900
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    9.9600/ 2
  • Ask / Lots
    11.1000/ 1
  • Open / Previous Close
    0.0000 / 10.3900
  • Day Range
    ---
  • 52 Week Range
    3.8880
    14.7480
  • Volume
    ---

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • May 14, 2024

  • May 13, 2024

      Show headlines and story abstract

    • 4:05PM ET on Monday May 13, 2024 by PR Newswire
      Companies Mentioned: INO

      -- BLA submission on track for INO-3107 in second half of 2024; if approved under accelerated approval pathway, could be first non-surgical treatment for recurrent respiratory papillomatosis (RRP)

      -- Planning initiation of confirmatory trial for INO-3107 based on FDA feedback

    • 4:05PM ET on Monday May 13, 2024 by Dow Jones
      Companies Mentioned: INO

    • 4:05PM ET on Monday May 13, 2024 by Dow Jones
      Companies Mentioned: INO
      entity 21,918 21,918 Convertible senior notes -- 16,770,654 --------------- --------------- Total current liabilities 23,400,945 42,570,228 Operating lease liability, net of current portion 11,271,257 11,032,066 Total liabilities 34,672,202 53,602,294 --------------- --------------- Stockholders' equity: Preferred stock -- -- Common stock 23,370 22,792 Additional paid-in capital 1,748,529,814 1,740,954,074 Accumulated deficit (1,653,435,007) (1,622,965,136) Accumulated other comprehensive loss (676,214) (662,601) --------------- --------------- Total Inovio Pharmaceuticals, Inc. stockholders' equity 94,441,963 117,349,129 Total liabilities and stockholders' equity $129,114,165 $170,951,423 =============== =============== Inovio Pharmaceuticals, Inc. CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Ended March 31, 2024 2023 Revenue from collaborative arrangements and other contracts $-- $114,943 -------------- -------------- Operating expenses: Research and development 20,913,790 30,176,511 General and administrative 10,571,179 13,890,610 Total operating expenses 31,484,969 44,067,121 -------------- -------------- Loss from operations (31,484,969) (43,952,178) Other income (expense): Interest income 1,500,290 2,207,171 Interest expense (177,833) (313,488) (Loss) gain on investment in affiliated entity (126,018) 616,639 Net unrealized gain on available-for-sale equity securities 500,877 3,218,215 Other expense, net (682,218) (2,425,676) Net loss $(30,469,871) $(40,649,317) Net loss per share Basic and diluted (1) $(1.31) $(1.89) Weighted average number of common shares outstanding Basic and diluted (1) 23,291,512 21,536,476 ============== ============== (1) Share and per share amounts have been restated to reflect the 1-for-12 reverse stock split effected in January 2024 on a retroactive basis for all periods presented.

Peers Headlines